TherapeuticsMD Stock Forecast, Price & News

TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions

Is TherapeuticsMD a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TherapeuticsMD stock.
View analyst ratings for TherapeuticsMD or view top-rated stocks.

How has TherapeuticsMD's stock price been impacted by COVID-19 (Coronavirus)?

TherapeuticsMD's stock was trading at $1.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TXMD stock has decreased by 68.4% and is now trading at $0.4799.
View which stocks have been most impacted by COVID-19.

When is TherapeuticsMD's next earnings date?

TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for TherapeuticsMD.

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD, Inc. (NASDAQ:TXMD) issued its quarterly earnings results on Thursday, November, 11th. The company reported ($0.11) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.01. During the same period in the prior year, the business posted ($0.10) EPS.
View TherapeuticsMD's earnings history.

What price target have analysts set for TXMD?

2 Wall Street analysts have issued 12-month price objectives for TherapeuticsMD's shares. Their forecasts range from $3.00 to $5.00. On average, they expect TherapeuticsMD's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 733.5% from the stock's current price.
View analysts' price targets for TherapeuticsMD or view top-rated stocks among Wall Street analysts.

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the following people:

• Robert G. Finizio, Chief Executive Officer & Director (LinkedIn Profile)
• Hugh O'Dowd, President
• James C. Darecca, Chief Financial Officer (LinkedIn Profile)
• Adam Miller, Chief Information Officer
• Sebastian Mirkin, Chief Medical Officer

Who are some of TherapeuticsMD's key competitors?

Some companies that are related to TherapeuticsMD include Phibro Animal Health (PAHC), Precigen (PGEN), Tyra Biosciences (TYRA), Kiniksa Pharmaceuticals (KNSA), Edgewise Therapeutics (EWTX), Arcutis Biotherapeutics (ARQT), Syndax Pharmaceuticals (SNDX), Aclaris Therapeutics (ACRS), CytoDyn (CYDY), Silence Therapeutics (SLN), Celularity (CELU), Northwest Biotherapeutics (NWBO), Radius Health (RDUS), Imago BioSciences (IMGO) and Y-mAbs Therapeutics (YMAB).
View all of TXMD's competitors.

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU).

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.97%), Morgan Stanley (1.97%), Geode Capital Management LLC (1.65%), Rubric Capital Management LP (1.26%), Sanders Morris Harris LLC (0.84%) and Renaissance Technologies LLC (0.35%). Company insiders that own TherapeuticsMD stock include Cooper C Collins, Edward Borkowski, James Darecca, Marlan D Walker, Michael C Donegan, Michael C Donegan, Paul Bisaro, Robert G Finizio, Tommy G Thompson and Tommy G Thompson.
View institutional ownership trends for TherapeuticsMD.

Which institutional investors are selling TherapeuticsMD stock?

TXMD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Millennium Management LLC, Knights of Columbus Asset Advisors LLC, Raymond James & Associates, Squarepoint Ops LLC, Alliancebernstein L.P., Citigroup Inc., and GSA Capital Partners LLP. Company insiders that have sold TherapeuticsMD company stock in the last year include Edward Borkowski, James Darecca, Marlan D Walker, Michael C Donegan, and Robert G Finizio.
View insider buying and selling activity for TherapeuticsMD or view top insider-selling stocks.

Which institutional investors are buying TherapeuticsMD stock?

TXMD stock was bought by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Renaissance Technologies LLC, Brandywine Global Investment Management LLC, Geode Capital Management LLC, Cubist Systematic Strategies LLC, BlackRock Inc., Goldman Sachs Group Inc., and Barclays PLC. Company insiders that have bought TherapeuticsMD stock in the last two years include Cooper C Collins, Paul Bisaro, Robert G Finizio, and Tommy G Thompson.
View insider buying and selling activity for TherapeuticsMD or or view top insider-buying stocks.

How do I buy shares of TherapeuticsMD?

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $0.48.

How much money does TherapeuticsMD make?

TherapeuticsMD has a market capitalization of $203.39 million and generates $64.87 million in revenue each year. The company earns $-183.52 million in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does TherapeuticsMD have?

TherapeuticsMD employs 400 workers across the globe.

What is TherapeuticsMD's official website?

The official website for TherapeuticsMD is www.therapeuticsmd.com.

Where are TherapeuticsMD's headquarters?

TherapeuticsMD is headquartered at 951 Yamato Road Suite 220, BOCA RATON FL, 33431.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at (561) 961-1900, via email at [email protected], or via fax at 561-431-3389.